Leukemia caused by retroviral insertional mutagenesis after stem-cell gene transfer has been reported in several experimental animals and in patients treated for Xlinked SCID. Here, we analyzed whether gene transfer into mature T cells bears the same genotoxic risk. To address this issue in an experimental 'worst case scenario', we transduced mature T cells and hematopoietic progenitor cells from C57BL/6 (Ly5.1) donor mice with high copy numbers of gammaretroviral vectors encoding the potent T cell oncogenes LMO2, TCL1 or ΔTrkA, a constitutively active mutant of TrkA. After transplantation into RAG-1 deficient recipients (Ly5.2), stem cell transplanted animals developed T cell lymphoma/leukemia for all investigated oncogenes with a characteristic phenotype and after characteristic latency periods.
Introduction
Gammaretroviral vectors integrate into the target cell genome thus supporting longterm transgene expression. They are among the best-established therapeutic vector systems and have successfully been used for gene transfer to hematopoietic stem cells (HSC) in the treatment of X-linked and ADA-deficient severe combined immunodeficiency (SCID). A limitation of retroviral gene transfer to HSC has been the risk of insertional mutagenesis, which was reported to lead to the preferential expansion of individual hematopoietic cell clones (clonal dominance) or even overt leukemia/lymphoma 1 . To date, four human cases of leukemia due to retroviral insertional mutagenesis have been described, all after initially successful treatment of X-linked SCID [2] [3] [4] . Three of these cases were associated with the activation of the T cell oncogene LMO2 near the retroviral integration site and all cases manifested as T cell lineage leukemias 5 .
It has been long known that leukemias can be linked to specific chromosomal translocations that juxtapose a strong promoter/enhancer element to a cellular oncogene, such as LMO2 or TCL1 6, 7 , thus up-regulating the expression of the oncogene. For several of these oncogenes, transgenic mouse models have confirmed their transforming activity 8, 9 . LMO2-transgenic mice develop T cell leukemia of an immature phenotype, while TCL1 is found to induce mature T cell malignancies. A deletion mutant of the receptor tyrosine kinase TrkA (ΔTrkA) for nerve growth factor was described that is constitutively active. ΔTrkA was found to generate acute myeloid leukemia as well as immature T cell leukemia after retroviral gene transfer and a very short latency period 10 .
Activation of potential oncogenes by retroviral insertion alone is not thought to be sufficient for transformation 11, 12 . One factor that may determine the penetrance of overt leukemia after oncogene activation is thought to be the level of cell lineage
For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From differentiation. In general, stem cells are supposed to be a preferred target for transformation as they already have the machinery for self-renewal activated, thus maintaining this activation may be simpler than turning it on de novo in a more differentiated cell. In addition, there is growing evidence that myeloid leukemias, originate in hematopoietic stem/ progenitor cells (HSCs/HPCs) or early myeloid progenitors 13, 14 . However, as compared to other mature cell lineages, fully differentiated lymphocytes claim a special position in hematopoiesis. They show long life-spans, sustained proliferation and the ability of self-renewal 15 . For B cell leukemias/lymphomas it was recently shown that fully maturated B-lymphocytes can still be transformed 16 .
Nevertheless, several observations indicate, that mature T cells are less susceptible to transformation than HSCs/HPCs. Human mature T cell leukemias/lymphomas are less frequent and occur predominantly in older patients after a long latency 17 . In clinical trials involving gene transfer into mature T cells, leukemia was never observed, despite follow-ups of more than 10 years [18] [19] [20] [21] . On the other hand, in none of the T cell trials such a high level of gene marking was achieved as in the SCID-X1 trial, and in SCID-X1 the selective advantage mediated by transgene expression may also have contributed to leukemic transformation. Therefore, the question of transformability of mature T cells remains to be clarified.
Since the answer to this question is of utmost relevance for clinical gene therapy, we aimed at directly comparing the susceptibility to transformation of mature T cells and 
Retroviral vectors/ cloning
SF91-ΔTrkA-IE was previously described 10 . The vector is referred to as SF91-ΔTrkA.
The vector MP91-wPRE was shown to support high transgene expression in mouse transplantation models 22, 23 . An internal ribosome entry site (IRES) from the Encephalomyocarditis virus (EMCV) was cloned in front of the gene for the enhanced green fluorescence protein (eGFP) into the vector, resulting in the control vector MP91-eGFP. The cDNAs of murine LMO2 and its HA-tagged version LMO2-HA were kindly provided by Olga Kustikova (Hannover Medical School, Department of Experimental Hematology, Hannover, Germany) and cloned into the described gammaretroviral vector MP91-eGFP in front of the IRES. HA-tag was located at the C-terminus of LMO2 after amino acid 158. The cDNA of the murine TCL1 was Western blot for ΔTrkA was performed as previously described 2,10,25 .
Primary antibodies used in this study included: rabbit anti-TrkA (763) 
Flow cytometry analysis and white blood counts of leukemic samples
Immediately prior to sacrifice and necropsy blood was obtained from symptomatic animals and a hemogram using a Scil vet animal blood counter (Scil animal care company GmbH, Viernheim, Germany) was prepared to determine the white blood count (WBC) in the periphery.
Flow cytometry analyses were carried out on blood and single cell suspensions of thymus, spleen, lymph nodes and bone marrow. The following anti-mouse monoclonal antibodies were used for staining: rat anti-mouse monoclonal antibodies Analyses were performed on a FACScalibur using the CellquestPro software (both from BD). All cell counts were performed on a CASY ® Cell Counter (Schärfe System, Reutlingen, Germany).
Histopathological analysis
Obviously sick mice with a high WBC were sacrificed for necropsy and examined for pathological abnormalities. After securing single cell suspensions of infiltrated organs for FACS analysis, lymph nodes, spleen, thymus, liver, kidney, lung, heart, brain and bone marrow were fixed in 10% Zinc-Formal-Fixx (Thermo Shandon, Pittsburgh, USA). Sections were prepared and stained with hematoxilin and eosin as a commercial service from MFD Diagnostics GmbH (Wendelsheim, Germany), according to the pathology data base RITA 26 . For histological examination a light microscope (Eclipse E1000m Nikon, Japan) with 4x, 20x and 40x lenses with a digital camera (DXM 1200, Nikon) was used.
LM-PCR, shotgun-cloning and insertion site analysis
Ligation-mediated polymerase chain reaction was performed as previously described [27] [28] [29] . Detailed descriptions for LM-PCR, shotgun-cloning and insertion site analysis are provided in supplementary material.
Results

Study design and retroviral vectors
To assess whether mature T cells could be transformed by overexpression of potent T cell oncogenes, we introduced gammaretroviral vectors that encode the potent T cell oncogenes LMO2, (LMO2-HA), TCL1, or ΔTrkA (a constitutively active mutant of TrkA, Figure 1A ). In addition, the vectors co-expressed eGFP as a marker gene via Transplanted animals were monitored for repopulation and development of leukemia/ lymphoma.
A few animals (3/54) developed CD8 + CD4 + double positive (DP) host-derived lymphomas from the RAG-1 deficient precursors after sublethal γ-irradiation (data not shown). Previous studies had already found that sublethal γ-irradiation induces differentiation of CD4 -/CD8 -into CD8 + /CD4 + thymocytes in RAG-1 and RAG-2 deficient mice in a T cell receptor beta chain-independent pathway 31,32 . Due to a longer observation period in the present study, the fate of these DP cells could be followed. We observed massive enlargement of the thymi that required sacrifice of the animals between weeks 18 and 40 after transplantation. Mice with host-derived tumors were not included in the data presented here.
After 12 -16 weeks, T cell transplanted animals (including the eGFP control group) developed massive colitis combined with weight loss, and were therefore sacrificed.
Minor antigen differences in the donor and recipient strain, although both on a In an analogous experimental set-up, TCL1 and ΔTrkA expression were also analyzed in thymocytes and lymphocytes after HSC/HPC and TC transplantation, respectively ( Figure 4C,D) . Again, MP91-eGFP transduced cells were used as negative controls. Thymocytes and T lymphocytes showed similar expression of TCL1 and ΔTrkA relative to eGFP, which again served also as a control for equal loading.
Oncogenes transform primary murine HSCs/HPCs
Following transplantation of oncogene-transduced HSCs/HPCs, all animals developed hematological malignancies after characteristic latency periods ( Figure 5 ). Figure S1A ), spleen (splenomegaly up to 0.6 g, control mice 0.09 g) and in some cases also lymph nodes (lymphoma up to 1.3 g for mesenteric, inguinal and superficial cervical lymph nodes, control mice 0.05g). In most of the cases (7 of 8 animals analyzed), white blood cell counts (WBC) were elevated (up to 200 x 10 3 / µl, control 15 x 10 3 / µl; Table 1 and Supplementary data: Table S1A ).
The cohort of MP91-TCL1 HSC/HPC transplanted animals showed a larger variety in tumor phenotypes. Leukemia/lymphoma developed 168-310 days post transplantation (Supplementary data: Table S1B ); thus leukemia developed much more rapidly than in TCL1 transgenic animals, which were reported to develop leukemia/lymphoma at 450-600 days of age 9 . Three of 9 animals developed leukemia/ lymphoma of a single positive (SP) phenotype, two were CD4+ and one was CD8+. Two out of 9 showed an immature DP phenotype and the remaining animals (4/9) developed CD19 positive tumors at later time points (259-310 days post transplantation), indicative of a B cell malignancy (Table 1) . TCL1-induced leukemias/lymphomas were characterized by massive enlargement of lymph nodes (up to 3.4g; Supplementary data Table S1B and Figure S1D ), thymus and spleen.
One of the transplanted animals (TCL1_A3) presented a distinct and unclear phenotype with massive subcutaneous infiltration and an enlarged liver (4g, control 1g; Supplementary data Table S1B ). Unfortunately, it was not possible to determine a specific lineage phenotype, as none of the tested markers (CD45.1, CD3, TCR, CD8, CD4, CD19, CD11b) stained cells of the subcutaneous infiltrate and only a very dim eGFP expression was observed. Again the majority (5/7) of mice with TCL1-lymphomas were leukemic with WBC up to 96 x 10 3 / µl (Supp . Table S1B ).
In more than half of the mice (5/9) transplanted with SF91-ΔTrkA high -transduced HSCs/HPCs we observed a hyper-acute myeloid proliferation, previously termed
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As previously described 10 , all animals that survived TL (4/9) subsequently developed lymphoblastic leukemia (ALL) of a DP phenotype (Table 1) , which was characterized by a gross thymic mass (up to 0.9 g). Interestingly, in the ΔTrkA low group, only the DP T-ALL phenotype was observed (9/9), with a latency of 76-85 days (Suppl. Table   S1D ) without any signs of TL.
For all oncogene groups, histopathology of diseased animals showed massive leukemic blast infiltrations in all analyzed organs including liver, lung, heart, kidney, spleen, brain, bone marrow and thymus (Supplementary data Figure S1 and data not shown). Genes in this window were analyzed for appearance in the RTCGD 33 and by gene ontology (GO) annotations, such as IDDb and PANTHERDB, which describe the biological functions of genes. Over-and underrepresented biological processes and PANTHERDB pathways were retrieved by comparing the sample set to a reference list consisting of all genes in the NCBI36 database using a multiple testing corrected binomial test.
In the dataset obtained with ΔTrkA low transduced cells, two hits, Prkcq and Mapk11, were found to be represented in several signaling pathways (Supplementary Table   S2 ). The LMO2 and TCL1 datasets did not contain any genes involved in multiple pathways.
Biological process GO annotation for the different groups showed that in all datasets genes involved in the high level process 'signal transduction' were overrepresented, while only few oncogenes and tumor suppressor genes were located next to or near the integrations.
When comparing genes within 100kb of the integrations in each group with the genes present in RTCGD, we obtained a strikingly large number of integrations that had at least one RTCGD gene within the +/-100kb window. Taken together with the fact that in all experimental groups the biologic process 'signal transduction' is found frequently, this might either show preferential retroviral integration near genes within these groups or provide a set of genes that collaborate with the transgene in oncogenesis (Supplementary S3). In one case, in the LMO2 group, a gene was found (Snx12) that was previously reported to be a possible collaboration partner of the oncogene 34 . A detailed list of all integration-sites for HSC/HPC derived tumors can be found in the supplementary data (Tables S4 A-LMO2, S4 B-TCL1, Table S5 shows the biological processes, which were found to be significantly over-or (Table S6A-EGFP and Table S6B -ΔTrkA).
Discussion
In the presented work, we directly compared the susceptibility of mature T cells and transplanted mice, respectively, were carefully monitored and found to be comparable. As the expression of eGFP was detectable throughout the whole observation time, an immunological control of potentially transformed mature T cells also seems unlikely, although eGFP has been described to be immunogenic in mice 35, 36 .
One limitation of the experimental setting is that only memory T cells were examined Unfortunately, tumor cells could not be grown in vitro for chromosomal analysis in this study. Karyotyping was successfully performed for only one LMO2-induced leukemia/lymphoma and showed a trisomy 17 but no translocations (data not shown).
However, the observation that HSCs/HPCs from RAG-1 deficient mice, which do not undergo significant TCR-recombination, were susceptible to transformation by LMO2 at a level comparable to wild type mice argues against a significant contribution of chromosomal translocation to leukemogenesis in the experimental setting used here (supplementary Figure S2) . T cell leukemia after LMO2 transduction of RAG-1 deficient HSCs/HPCs was also described by others in a double transgenic mouse model 41 . This observation leads to the conclusion that the role of TCR recombination at least in the tumorigenesis of LMO2 is negligible.
An interesting potential mechanism of controlling leukemogenesis in mature T cells could be the competition of T lymphocytes with a similar TCR for a stimulatory niche that consists of the corresponding MHC/self-peptide complexes. This clonal competition restricts the size of T cell clones and has been described as a homeostatic mechanism to preserve the polyclonality of T cells 42 . Accordingly, expansion of a pre-malignant T cell clone that still has a certain dependence on MHC/self-peptide interaction for survival would be restricted by the size of the corresponding MHC/self-peptide niche. Studies are under way to test this hypothesis. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
